The Conversation (0)
Burcon Nutrascience Corporation (TSX: BU,OTC:BRCND): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU,OTC:BRCND). During 1Q26, Burcon advanced meaningfully in its commercialization strategy. Within 90 days of commissioning its Galesburg facility, the Company achieved first commercial production of its next-generation Peazazz® C pea protein and debuted FavaPro fava protein. Initial shipments of Peazazz® C were completed during the quarter, supported by strong market reception and customer trials. Burcon also entered into a $6.8 million multi-year production agreement, underpinning its 2025 revenue target of $1-3 million. The Galesburg facility integrates Burcon's proprietary protein technologies, enabling scalable, versatile production across multiple plant-based proteins. This operational flexibility positions the Company to meet evolving customer needs quickly and with consistent quality, while unlocking a total addressable pea protein market estimated at US$215 million to US$392 million.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Achieved first commercial production and initial sales of Peazazz® C pea protein; launched FavaPro fava protein following strong customer response.
Entered into $6.8M multi-year production agreement, providing baseline recurring revenue.
Q1 FY26 revenue rose 44% YoY to $0.34M; startup costs at Galesburg facility impacted margins, with expenses now at "new normal" levels.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262569